Our results tend to support these overall findings of reliable remodelling of DBM to new bone. The histological analysis showed significant new bone formation and decreasing residual DBM material in ...
As previously disclosed, in late Q3 2022, the Company began to experience material supply issues related to its ALLOCYTE ® Advanced Cellular Bone Matrix (“ALLOCYTE”) product line. The supply ...
Molecular Matrix, a privately held company that arose from the University of California, Davis, received FDA approval for its Osteo-P bone graft substitute technology. Osteo-P is a non-mineralized, ...
BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) is a clinical-stage biotechnology company focused on transforming the multibillion-dollar spine fusion and bone regeneration market ...
Xtant Medical Expands Product Portfolio with Launch of its own Viable Bone Matrix, OsteoVive(R) Plus
Sean Browne, President and CEO of Xtant Medical, stated, "New product launches are a key component of our strategy to drive margin improvement on higher sales and generate positive operating cash flow ...
ViviGen ® Cellular Bone Matrix, an innovative cellular allograft developed by LifeNet Health and marketed in collaboration with DePuy Synthes Spine, received one of the highest honors in spinal ...
A new study of the PhyloBone project of the University of Turku, Finland, identifies hundreds of non-collagenous proteins in the bone matrix that may play regulatory roles in bone formation and ...
SAN FRANCISCO & PARSIPPANY, N.J.--(BUSINESS WIRE)--Ossium Health®, a bioengineering company that established a first-of-its-kind bone marrow banking platform, has entered into a collaborative ...
Bone implants often fail to fully integrate with surrounding tissue, limiting their effectiveness in regeneration. A natural but often overlooked cellular process could hold the key to better outcomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results